Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New frown line injection shows promise in early trial

NCT ID NCT05100199

Symptom relief Sponsor: Allergan Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study tested a new botulinum toxin injection (OnabotulinumtoxinA X) for treating moderate to severe frown lines between the eyebrows. 328 adults received either the active injection or a placebo. Researchers measured wrinkle improvement and tracked any side effects. The goal was to find the best dose and confirm safety.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
OnabotulinumtoxinA X (a botulinum toxin type A injection)
What this could lead to
If successful, this could lead to a new treatment option for reducing frown lines between the eyebrows.
What could go wrong
This is an early Phase 2 dose-ranging study, so results may not confirm effectiveness or safety. Side effects like injection site reactions or muscle weakness are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

328 people

The number who actually took part.

Started

Oct 2021

Finished

Dec 2022

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participant has sufficient visual acuity without the use of eyeglasses (contact lens use is acceptable) to accurately assess their facial lines, in the opinion of the investigator. * Participant has moderate or severe GL at maximum frown. Exclusion Criteria: * History of known immunization to any botulinum toxin serotype. * History of known hypersensitivity to any botulinum toxin serotype, or any other constituents of the study drug or its excipients, and/or other products in the same class. * Presence or history of any medical condition that may place the participant at increased risk following exposure to OnabotulinumtoxinA X or interfere with the study evaluation, including: * Diagnosed myasthenia gravis, Lambert-Eaton syndrome, amyotrophic lateral sclerosis, or any other significant disease that might interfere with neuromuscular function. * Facial nerve palsy. * Infection or dermatological condition at the site of study drug injection.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Glabellar lines are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Glabellar lines

Contacts and locations

Locations

  • Advanced Research Associates - Glendale /ID# 230418

    Glendale, Arizona, 85308, United States

  • Aesthetic Solutions /ID# 230716

    Chapel Hill, North Carolina, 27517-9901, United States

  • Aventiv Research Dublin /ID# 232546

    Dublin, Ohio, 43016, United States

  • Baumann Cosmetic and Research Institute /ID# 232545

    Miami, Florida, 33137-3254, United States

  • Center for Dermatology and Dermatologic Surgery /ID# 230684

    Washington D.C., District of Columbia, 20037-1445, United States

  • Coleman Center For Cosmetic Dermatologic Surgery /ID# 230693

    Metairie, Louisiana, 70006, United States

  • Etre Cosmetic Dermatology and Laser Center /ID# 230437

    New Orleans, Louisiana, 70130-4353, United States

  • Laser & Skin Surgery Center of New York /ID# 230683

    New York, New York, 10016-4974, United States

  • Premier Clinical Research /ID# 230682

    Spokane, Washington, 99202, United States

  • Research Institute of the Southeast, LLC /ID# 230436

    West Palm Beach, Florida, 33401-2712, United States

  • SLUCare Cosmetic Dermatology /ID# 230333

    St Louis, Missouri, 63122-3379, United States

  • Skin Search of Rochester Inc. /ID# 242540

    Rochester, New York, 14623, United States

  • Steven Fagien MD Aesthetic Eyelid Plastic Surgery /ID# 232542

    Boca Raton, Florida, 33431-6465, United States

  • The Eye Research Foundation /ID# 232544

    Newport Beach, California, 92663-3637, United States

  • The Research Center at The Maas Clinic /ID# 230685

    San Francisco, California, 94115-1809, United States

  • Westlake Dermatology & Cosmetic Surgery - Westlake /ID# 232543

    Austin, Texas, 78746-4720, United States

  • Westside Aesthetics /ID# 230305

    Los Angeles, California, 90025-1708, United States

  • Wilmington Dermatology Center /ID# 242544

    Wilmington, North Carolina, 28403, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.